Dr Paula McClean
Lecturer in Stratified Medicine (Diabetes and Mental Health)
School of Biomedical Sciences
Early administration of the GIP receptor antagonist (Pro(3))GIP counters development of hyperglycaemia, glucose intolerance and insulin resistance in genetic obesity
Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets
Effects of GIP-receptor antagonism in a streptozotocin-induced model of insulin deficiency
Effects of subchronic treatment with the long-acting glucose-dependent insulinotropic polypeptide receptor agonist, N-AcGIP, on glucose homeostasis in Streptozotocin-induced diabetes
Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide
Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice
Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice
Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro(3))GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice
Effects of daily administration of the glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, N-Acetyl-GIP, in streptozotocin-incluced diabetic mice
GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet
Antidiabetic effects of sub-chronic administration of stable incretin mimetics N-AcGIP and exendin-4 (1-39) amide in obese-diabetic mice
Daily administration of the GIP-R antagonist (Pro(3))GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro(3))GIP
(Pro(3)) GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy
Novel GLP-1 analogues cross the blood brain barrier and enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease
Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice
Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes
Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease.
Structure function studies with glucagon related peptides reveal glucagon receptor antagonist activities in vitro and in vivo
Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice
Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease
The novel GLP-1 analogue liraglutide has neuroprotective properties in a mouse model of Alzheimer's disease
The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.
1H NMR metabolomics investigation of an Alzheimer’s disease (AD) mouse model pinpoints important biochemical disturbances in brain and plasma
The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.
Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease
A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1ΔE9 mouse model of Alzheimer's disease.
Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease
Xenin-25, a promising new preclinical candidate for neurodegenerative diseases (U515)
Novel treatments for Alzheimer’s disease (AD) using stable analogues of GIP (U140A)